Compare ZVIA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | IPSC |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 189.7M |
| IPO Year | 2021 | 2021 |
| Metric | ZVIA | IPSC |
|---|---|---|
| Price | $1.91 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $5.18 | $3.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.9M |
| Earning Date | 02-25-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $162,849,000.00 | $113,337,000.00 |
| Revenue This Year | $7.60 | $1,590.09 |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.17 | ★ 4122.69 |
| 52 Week Low | $1.66 | $0.34 |
| 52 Week High | $4.51 | $2.71 |
| Indicator | ZVIA | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 65.08 |
| Support Level | $1.81 | $2.08 |
| Resistance Level | $2.12 | $2.71 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 54.84 | 65.95 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.